Consensus Ipsen

Equities

Real-time Euronext Paris Other stock markets 06:30:34 2024-04-19 am EDT			5-day change	1st Jan Change
106.8 ^EUR	+0.47%		-2.38%	-1.02%

Apr. 15	Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	CF
Apr. 02	Ipsen: worldwide licensing agreement with Sutro Biopharma	CF

59251ba1af4d0.rO_pHXMgCTGX2k-mmlJ83omiKPynPRA51uJrGGa_zg0.zZ-eVDZRXWnhuBv03zdE6uOWRa3GV3EBk6Elbhz5qEL0mIxyAUNeVs2WOA~fc07eec3dbfbf19962033e6c44d1b000

IPSEN : Ipsen’s underlying fundamentals remain promising	Mar. 13
Deutsche Bank Reduces Ipsen PT, Keeps Hold Rating	Feb. 16	MT
IPSEN : Deutsche Bank cuts its target	Feb. 16	CF
IPSEN : UBS reiterates its buy recommendation	Feb. 14	CF
IPSEN : In line Q4 sales; lower-than-expected 2024 guidance	Feb. 08
IPSEN : Deutsche Bank lowers its target price	Dec. 15	CF
IPSEN : Ipsen outlined some promising mid-term takeaways at the CMD	Dec. 08
IPSEN : UBS remains Buy after CMD	Dec. 08	CF
IPSEN : RBC maintains 'in-line performance' rating	Nov. 29	CF
IPSEN : Jefferies downgrades recommendation to 'hold	Nov. 20	CF
IPSEN : Modest Q3 sales growth; guidance unchanged	23-10-26
UBS Upgrades Ipsen to Buy from Neutral, Boosts PT	23-09-12	MT
IPSEN : A compelling small Pharma	23-08-07
IPSEN : Healthy Q2 sales + a guidance upgrade	23-07-27
IPSEN : Healthy Q1 sales; full-year guidance maintained	23-04-27
IPSEN : Promising end to 2022	23-04-17
IPSEN : Promising end to 2022	23-02-09
Roche’s Alzheimer’s failure has sector-wide implications	22-11-14
IPSEN : Healthy Q3 sales; guidance reiterated	22-10-27
IPSEN : Strong Q2 + guidance upgrade; an atypical solid small pharma	22-07-28
IPSEN : 2022 begins on a healthy note	22-04-27
IPSEN : Promising results, and takeaways for 2022 and beyond	22-02-14
IPSEN : Strong Q3 prompts guidance upgrade	21-10-23
IPSEN : Another setback for Palovarotene	21-08-16
IPSEN : Neurosciences and oncology ensure a strong beat in Q2; FY21 outlook raised	21-07-29